| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 40 | 60 | 130 | 84,680 | 10,650 |
| Sales Growth | -33.33% | -53.85% | -99.85% | +695.12% | +37.24% |
| Net Income | -274,450 | -342,990 | -234,630 | -183,120 | -250,220 |
| Net Income Growth | +19.98% | -46.18% | -28.13% | +26.82% | -22.37% |
Lyell Immunopharma Inc (LYEL)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Lyell Immunopharma Inc. is a T cell reprogramming company dedicated to the mastery of T cells to cure patients with solid tumors. Lyell Immunopharma Inc. is based in SOUTH SAN FRANCISCO, Calif.
Fiscal Year End Date: 12/31